Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Lymphoblastic LeukaemiaAcute Myeloid LeukemiaMyelodysplastic NeoplasmsStem Cell Transplantation, AllogeneicSubgroupICD10C91.0-C92.0-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-D46.-MeSHHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMyelodysplastic SyndromesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningSequenceChemotherapyChemo-substanceAzacitidineLenalidomideChemo-substanceAzacitidineLenalidomideChemo-substanceAzacitidineLenalidomideChemo-substanceAzacitidineLenalidomideNo. Substances12 RadiotherapySupportive therapySupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamMelphalanMethylprednisoloneParacetamolPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamMelphalanMethylprednisoloneParacetamolPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamMelphalanMethylprednisoloneParacetamolPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamMelphalanMethylprednisoloneParacetamolPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirNo. Substances310111216Protocol classificationTherapy classificationalternativecurrent standardIntensityKonditionierung, intensitäts- oder dosisreduziert (RIC)Konditionierung, myeloablativ (MAC)Standard doseTherapy indicationRelapse therapyTherapy phaseallogene StammzelltransplantationTherapy intentioncurativecurative or palliativepalliativeRisksBleedingCardiotoxicityEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityHyperbilirubinemiaInfectionsNeurotoxicityNeutropeniaPainPneumoniaRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorBeelen DWCiurea SOCraddock CEstey ELübbert MMarks RPlatzbecker URambaldi ASchroeder TShimoni ASolomon SRDiseaseAML, 40-65 Jahre, ECOG 0-2, < 5% BlastenAML, MDS, CML, NHL, ungeeignet für konventionelle intensive KonditionierungAML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML/ALL/MDS, allogene SCTAML/MDS, 18-65 Jahre, < 5% BlastenAML/MDS, 18-70 Jahre, AML in kompletter hämatologischer Remission (unter 5% Blasten) oder MDS (unter 20% Blasten), HCT-CI Score über 2AML/MDS, allogene StammzelltransplantationAML/MDS, ungeeignet für konventionelle intensive KonditionierungAML/MDS, unter 55 JahreDrohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)OriginAlbert-Ludwigs University Medical Center, Freiburg, GermanyCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialDepartment of Haematology and Oncology, Albert-Ludwigs University Medical Center, FreiburgDivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, ItalyOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyThe Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GeorgiaThe Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, IsraelThe University of Texas M. D. Anderson Cancer Center, Houston, USAUniversity of Birmingham, Birmingham, United KingdomUniversity of Texas MD Anderson Cancer Center, Houston, USAWest German Cancer Centre, University of Duisburg-Essen, Essen, GermanyProtokolle in Überarbeitung 12 protocols foundAzacitidin 100, akute myeloische Leukämie und myelodysplastisches Syndrom nach allogener Stammzelltransplantation (PID2302 V1.0)Azacitidin 100, akute myeloische Leukämie und myelodysplastisches Syndrom nach allogener Stammzelltransplantation, Variante 1 (PID2320 V1.0)Azacitidin 75 / Lenalidomid 25, akute myeloische Leukämie und myelodysplastisches Syndrom nach allogener Stammzelltransplantation (PID827 V1.2)Azacitidin 75, akute myeloische Leukämie und myelodysplastisches Syndrom nach allogener Stammzelltransplantation (PID2327 V1.0)Fludarabin 30 / Carmustin 150 / Melphalan 110, allogene Stammzelltransplantation, RIC (PID880 V1.0)Fludarabin 30 / Carmustin 200 / Melphalan 140, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, RIC (PID1705 V1.0)Fludarabin 30 / Melphalan 100, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, RIC (PID3225 V1.0)Fludarabin 30 / TBI 12, allogene Stammzelltransplantation, MAC (PID3219 V1.0)Fludarabin 30 / Treosulfan 10, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, MAC (PID1706 V1.0)Fludarabine 40 / Busulfan 0.8 / Anti-thymocyte Globulin (Rabbit) (0.5/2.0/2.5), Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation, MAC (PID885 V1.0)Fludarabin 40 / Busulfan 3,2 / Antithymozytenglobulin vom Kaninchen 10, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, MAC (PID881 V1.0)Melphalan 140 / Thiotepa 10 / Fludarabin 40, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, RIC (PID1738 V1.0)
